Hypertension Guidelines JNC Recommendations. Robert E. Bulow DO FACOI, FACC

Similar documents
None. Disclosure: Relationships with Industry Conflicts of Interests. Learning Objectives: Participants will be able to:

DISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.

Blood Pressure LIMBO How Low To Go?

JNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH

Hypertension JNC 8 (2014)

JNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

JNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines

Treating Hypertension in 2018: What Makes the Most Sense Today?

NIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

Managing Hypertension in 2018

Hypertension and the SPRINT Trial: Is Lower Better

RISE, FALL AND RESURRECTION OF RENAL DENERVATION. Michael A. Weber, MD State University of New York Downstate College of Medicine

New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets

The Latest Generation of Clinical

Objectives. Describe results and implications of recent landmark hypertension trials

2017 High Blood Pressure Clinical Practice Guideline

Best Practices in Cardiac Care: Getting with the Guidelines

HYPERTENSION: UPDATE 2018

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Long-Term Care Updates

Status Report on the NHLBI-Sponsored CVD Prevention Guidelines

Jared Moore, MD, FACP

Evolving Concepts on Hypertension: Implications of Three Guidelines (JNC 8 Panel, ESH/ESC, NICE/BSH)

Patient is healthy with no chronic disease or significant risk factors [16%].

Hypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic

Hypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital

Renal Denervation. by Walead Latif, DO, MBA, CPE Assistant Clinical Professor Rutgers Medical School

Life After CORAL: What Did CORAL Prove? David Paul Slovut, MD, PhD Co-director TAVR, Dir of Advanced Intervention

Catheter-Based Renal Sympathetic Denervation in the Management of Resistant Hypertension

2. Measurement Specifications 3. Patient Messaging 4. Provider Messaging Other Recent Guidelines

Osama Sanad (MD) Prof. of Cardiology Benha University 2016

Disclosures. Hypertension: Nationwide Dilemma. Learning Objectives. What s Currently Recommended? Specific Concerns 3/9/2012

University of Padova, Padua, Italy, and HARVEST Study Group, Italy

Implications of Drug-related Increases in Blood Pressure

DISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE

Hypertension 2015: Recent Evidence that Will Change Your Practice

Aquifer Hypertension Guidelines Module

Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension)

HYPERTENSION GUIDELINES WHERE ARE WE IN 2014

Diversity and HTN: Approaches to optimal BP control in AfricanAmericans

Renal Denervation For Hypertension: Status Update

KDIGO Controversies Conference on Blood Pressure in CKD

Update on Current Trends in Hypertension Management

New Hypertension Guidelines: Why the change? Neil Brummond, M.D. Avera Medical Group Internal Medicine Sioux Falls, SD

Disclosure. No relevant financial relationships. Placebo-Controlled Statin Trials

Hypertension Guidelines 2017

Stephen G. Worthley 1, Gerard T. Wilkins 2, Mark W. Webster 3,Joseph K. Montarello 1, Paul T. Antonis 4, Robert J. Whitbourn 5, Roderic J.

T. Suithichaiyakul Cardiomed Chula

Hypertension Management Controversies in the Elderly Patient

Managing HTN in the Elderly: How Low to Go

Working Together to Prevent Diabetes

Hypertension Management: A Moving Target

Hypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington

Hypertension Update Clinical Controversies Regarding Age and Race

Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures

Treating Hypertension from

Disclosure. Instead of JNC 8. Proposed Reasons for Delays. Outline 6/10/2013. Member of JNC 8 panel No other disclosures. Daniel T.

Diabetes and Hypertension

Blood Pressure Measurement in SPRINT

Renal Artery Denervation New Concepts in Hypertension Treatment

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Management of Lipid Disorders and Hypertension: Implications of the New Guidelines

2/10/2014. Hypertension: Highlights of Hypertension Guidelines: Making the Most of Limited Evidence. Issues with contemporary guidelines

Todd S. Perlstein, MD FIFTH ANNUAL SYMPOSIUM

TIP. Documentation and coding guide. Disease definitions* Prevalence and statistics associated with HTN**

Health Benefits of Lowering Sodium Intake in the US

Managing Hypertension in 2016

Understanding the importance of blood pressure control An overview of new guidelines: How do they impact daily current management?

2/9/2017. Financial Disclosures/Unapproved Use. Achieving Harmony in Blood Pressure Guidelines Around the Globe. Roger S. Blumenthal, MD.

HYPERTENSION GUIDELINES: BEING NORMAL JUST GOT HARDER

Yuqing Zhang, M.D., FESC Department of Cardiology, Fu Wai Hospital. CAMS & PUMC, Beijing, China

New Clinical Trends in Geriatric Medicine. April 8, 2016 Amanda Lathia, MD, MPhil Staff, Center for Geriatric Medicine

How do we diagnose hypertension today? Presentation Subtitle

4/24/15. AHA/ACC 2013 Guideline Key Points

HYPERTENSION: ARE WE GOING TOO LOW?

Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly

Established Risk Factors for Coronary Heart Disease (CHD)

SAURIN GANDHI, AZCOM Evidence-Based Guideline for the Management of High Blood Pressure in Adults (JNC 8)

New Lipid Guidelines. PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN: Implications of the New Guidelines for Hypertension and Lipids.

Lorne A. Becker MD Emeritus Professor SUNY Upstate Medical University. Co-Chair, Cochrane Collaboration Steering Group

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016

Disclosure of Relationships

Advancing Behavioral and Social Sciences Research to Meet the Challenges of Obesity and Diabetes

Transcatheter Perivascular Alcohol- Mediated Renal Denervation

Objective & Outline. How the JNC Process Has Evolved. Expertise Represented on JNC 8 Panel

Working Together to Prevent Diabetes

Recent Hypertension Guidelines

CARDIOVASCULAR RISK FACTORS & TARGET ORGAN DAMAGE IN GREEK HYPERTENSIVES

Phase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018

Metabolic Syndrome: A Preventable & Treatable Cluster of Conditions

Hypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)

Conflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines

The Future of Renal Denervation

Renal Sympathetic Denervation for HTN

Real World Experience with Renal Denervation Therapy

Transcription:

Hypertension Guidelines JNC Recommendations Robert E. Bulow DO FACOI, FACC

None Disclosures

Question At what blood pressure should pharmacologic therapy be initiated in the non diabetic pt with age greater than 60 years of age? 20% 1. 120/80 20% 20% 20% 20% 2. 130/85 3. 140/90 4. 150/90 5. 160/100 10 Countdown

Objectives 1. When should hypertension be treated with antihypertensive medications? 2. Is there an age factor that influences antihypertensive therapy? 3. How are diabetic and chronic kidney disease patients treated differently for hypertension compared to the general population?

Case 66 y/o Black male presents to PCP with BP 144/86, HR 72 bpm, BMI 32, waist circumference 52 inches. Non diabetic egfr 95 Non smoker Sedentary lifestyle 2-3 alcoholic beverages daily. Recommendations?

Treatment of HTN Background / History History of NHLBI & Guidelines JNC-7 JNC-(8) Future Guidelines Renal denervation

Background HTN remains one of the most important and preventable contributions to disease and death. 65+ million Americans have HTN World wide 1 billion+ have HTN Greater than 9 million globally die of HTN related diseases annually In the US < 50% of people with BP>140/90 are aware of it and of those receiving therapy <33% reach target blood pressures Lowering SBP by 10mmHg reduces coronary heart disease risk by 25%, and risk of stroke by 33%.

History NHLBI and JNC 1940 FDR dedicates NIH Bethesda Campus 1972 Elliot Richardson Secretary of the US Dept of Health, Education, and Welfare established National Hypertensive Program. 1976 JNC1 1980 JNC2 1984 JNC3 1988 JNC4 1992 JNC5 1997 JNC6 2003 JNC7 2013 JNC (8)

JNC 7 The purpose of JNC reports is to synthesize the available scientific evidence and offer guidance to busy primary care physicians. Dr. Aram V. Chobanian M.D. chair Executive Committee began work on the Express version Dec 2002 and was published May 2003. Evidence based approach including observational, RCT, and meta analysis s. Consensus based guideline, not a rigorous guideline based on IOM Extensive review and guideline.

JNC 8 Panel created for JNC8 in 2008 Dr. Paul James Chair Panel members 45 External Methodology team performed the literature review Panel members created evidence statements from the literature review Review process included the time period Jan1,1966 to Dec 31, 2009. Dec 2009 August 2013. Jan 2013 guideline submitted to external peer review by NHLBI to 20 reviewers Statement by NHLBI in June 2013, out of guideline buisiness JNC panel releases guideline in Dec 2013, no endorsement

Literature Review Rigorous criteria RCT adults aged 18 or greater Studies with sample sizes smaller than 100 or follow up less than 1 year excluded HTN patients Hard endpoints IOM Institute of medicine Standards for systematic reviews Development of trustworthy guidelines

Definition of HTN

JNC 8

Comparison to JNC7

Evidence

Recommendation

Recommendations

Antihypertensive drugs

Strategies

Guidelines

Lifestyle Changes

Case

Future Guidelines NHLBI to refocus its health education agenda on their core mission of knowledge generation and synthesis by supporting and producing rigorous systematic reviews that can then be used by other collaborating organizations ti generate guidelines. Oct 2013 AHA/ACC announce that jointly they will assume the governance and management of these preventive guidelines

Question At what age should pharmacologic therapy be initiated in the non diabetic greater than 60 years of age? 1. 120/80 2.130/85 3.140/90 4. 150/90 5.160/100

Question At what age should pharmacologic therapy be initiated in the non diabetic greater than 60 years of age? 20% 1. 120/80 20% 20% 20% 20% 2. 130/85 3. 140/90 4. 150/90 5. 160/100 10 Countdown

At what age should pharmacologic therapy be initiated in the non diabetic greater than 60 years o... 1 20% 20% 1 20% 20% 1 20% 20% 1 20% 20% 1 20% 20% First Slide Second Slide

Renal Denervation

Afferent Renal Nerve Signaling

Catheter Based Approach

Change in Office DBP and SBP in the Simplicity HTN-2 Trial

Two year follow up in the Simplicity HTN-1 Trial

Conclusions

Confidence what you start out with before you understand the situation Anonymous